Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mayo Clinic
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
Cancer deals involve City of Hope/Chimeric, CARISMA/NYU, Sorrento/Mayo Clinic, Rain/Drexel, Diaprost/Memorial Sloan Kettering, Alkido/University of Kentucky. Plus, research collaborations in brief.
The diagnostics industry could benefit from a greater focus on real-world evidence linked to the COVID-19 pandemic, according to experts from the US FDA and industry.
Tech Transfer Roundup: Anixa Thinks Cleveland Clinic IP Offers Potential In Triple-Negative Breast Cancer
Anixa obtains cancer vaccine targeted to proteins common in breast cancer from Cleveland Clinic. Arxx licenses Cancer Research UK antibody that targets tumor microenvironment.
- Academic and Research Institutions
- Other Names / Subsidiaries
- Mayo Clinic Laboratories
- Mayo Medical Laboratories